Back to results

CompletedPhase 3

A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)

NCT03665038

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Sage Investigational Site

Tempe, Arizona, United States

+16 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2018-09-07
Enrollment: 28 participants
Sponsor: Supernus Pharmaceuticals, Inc.
Purpose: treatment

Locations (17)

Sage Investigational SiteTempe, Arizona, United States
Sage Investigational SiteNorth Little Rock, Arkansas, United States
Sage Investigational SiteMiramar, Florida, United States
Sage Investigational SiteOrlando, Florida, United States
Sage Investigational SitePensacola, Florida, United States
Sage Investigational SitePinellas Park, Florida, United States
Sage Investigational SitePompano Beach, Florida, United States
Sage Investigational SiteAtlanta, Georgia, United States
Sage Investigational SiteDecatur, Georgia, United States
Sage Investigational SiteEdgewood, Kentucky, United States
Sage Investigational SiteOwensboro, Kentucky, United States
Sage Investigational SiteFlowood, Mississippi, United States
Sage Investigational SiteJackson, Mississippi, United States
Sage Investigational SiteChapel Hill, North Carolina, United States
Sage Investigational SiteMiddleburg Heights, Ohio, United States
Sage Investigational SiteHouston, Texas, United States
Sage Investigational SiteLeague City, Texas, United States

A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD) — TrialFind